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Abstract: Retinoic acid (RA) has profound effects on epidermal homeo-
stasis; however, the molecular mechanisms by which retinoids regulate kera-
tinocyte cell proliferation and differentiation are not well understood.
Here we report that mRNA expression of heparin-binding EGF-like
growth factor (HB-EGF), a member of the EGF family of growth factors,
is induced by RA in human keratinocytes and skin, and is overexpressed
in the context of epidermal hyperplasia in vivo. Treatment of normal adult
human keratinocytes with micromolar concentrations of RA significantly
induced the expression of HB-EGF. The response was efficiently blocked
by specific inhibitors of ErbB tyrosine kinase activity, MAP kinase kinase
(MEK), or p38 stress-activated protein kinase. RA also enhanced the in-
duction of HB-EGF mRNA in human skin organ culture, an ex vivo
model system displaying many similarities to wound healing in vivo. HB- Key words: heparin-binding EGF-like growth
EGF transcripts were markedly increased in human skin by topical treat- factor – retinoic acid – psoriasis – signal
ment with RA under conditions known to provoke epidermal hyperplasia. transduction – keratinocytes – gene expression
HB-EGF transcripts were also markedly overexpressed in the hyperplas- Dr Elder, 3312 CCGC, Cancer Center and
tic epidermis of psoriatic lesions, relative to normal skin. These results Geriatrics Center Building, University of
support the hypothesis that the effects of RA on epidermal hyperplasia are Michigan, Ann Arbor, MI 48109-0932, USA
Tel.: (734) 763-0355. Fax: (734) 763-4575mediated at least in part by HB-EGF, and suggest that signal transduction
e-mail jelder/umich.edumechanisms other than or in addition to nuclear RA receptors contribute
to this effect. Accepted for publication 2 April 1998
Introduction
Retinoids, the natural and synthetic metabolites
and analogs of vitamin A (retinol), are important
regulators of epidermal proliferation and differen-
tiation (1). These compounds, among which all-
trans retinoic acid (RA) is the major naturally oc-
curring biologically active form, are thought to
Abbreviations:
EGF: epidermal growth factor; TGF-a: transforming growth
factor-a; HB-EGF: heparin-binding EGF-like growth factor;
RA: retinoic acid; KBM: keratinocyte basal medium; KGM:
keratinocyte growth medium; NHK: normal human keratino-
cytes; RARE: retinoic acid response element.
*Parts of this work were presented at the annual meeting of the
Society of Investigative Dermatology, Washington, DC, April
1996.
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mediate their effects by binding to nuclear recep-
tors belonging to the steroid hormone receptor su-
perfamily of ligand-inducible transcription factors
(2). Two families of RA receptors have been iden-
tified, called retinoic acid receptors (RAR) and re-
tinoid X receptors (RXR), and each family con-
sists of 3 members expressed as a series of isotypes
(3). Following ligand binding these transcription
factors have been shown to form homo- and/or
heterodimers: RARs heterodimerize with RXRs
and bind to specific sequences called retinoic acid
responsive elements (RARE), whereas RXRs can
homodimerize or form heterodimers with several
other members of the steroid receptor superfamily
(4). RARE have been identified in the promoters
of several genes including cellular retinoic acid
binding protein II (CRABP-II), mouse and rat
cellular retinol binding protein (CRBP) and the
Stoll & Elder
hyperproliferative keratin K6 (5–8). However,
none of these genes have been shown to be directly
responsible for the robust epidermal proliferation
which occurs in response to topical retinoid treat-
ment (9, 10).
In order to better understand the molecular
mechanisms involved in retinoid regulation of epi-
thelial proliferation, we tested whether heparin-
binding EGF-like growth factor (HB-EGF), a
member of the EGF-like growth factor family (11),
is regulated by RA treatment of epidermal cells.
Several members of this family, including trans-
forming growth factor-a (TGF-a) and amphiregul-
in (AR) in addition to HB-EGF, are expressed by
keratinocytes in an autocrine fashion (12–14).
Among these factors, HB-EGF is markedly over-
expressed in wound healing (15–17) and AR is
overexpressed in a variety of dermatoses character-
ized by epidermal hyperproliferation (18). How-
ever, we found that AR was expressed at much
lower levels than was HB-EGF in actual healing
skin wounds (15, 19). Here we report that HB-
EGF expression is markedly induced in response
to retinoid treatment of cultured keratinocytes as
well as in human skin in vivo and in organ culture.
We also present inhibitor studies that implicate sig-
nal transduction mechanisms other than or in ad-
dition to ligand-dependent activation of nuclear re-
ceptors in the keratinocyte response to RA. Fi-
nally, we demonstrate for the first time the
overexpression of HB-EGF in psoriatic lesions,




RA and the corticosteroid triamcinolone acetonide
were purchased from Sigma (St Louis, MO, USA).
The synthetic retinoids P-[(E)-2-(5,6,7,8-tetrahy-
dro-5,5,8,8-tetramethyl-2-naphtalenyl)-1-propenyl]
benzoic acid (TTNPB) and M-[(E)-2-(5,6,7,8-tetra-
hydro-5,5,8,8-tetramethyl-2-naphtalenyl)-1-prope-
nyl] benzoic acid (meta-carboxy TTNPB, mc-
TTNPB) were supplied by Dr James Mezick of the
R.W. Johnson Pharmaceutical Research Institute,
Raritan, NJ, USA. The synthetic 1,25-dihydroxy-
vitamin D3 analogue MC903 (calcipotriol) was the
generous gift of Dr Knud Kragballe, University of
Aarhus, Aarhus, Denmark. The EGFR tyrosine
kinase inhibitor PD153035 (20) was generously
provided by Drs D. Fry and W. R. Leopold (Parke
Davis Pharmaceutical Research, Ann Arbor, MI,
USA), the MAP kinase kinase (MEK) inhibitor
PD98059 (21) and the p38 stress-activated protein
kinase inhibitor SB202190 were purchased from
Calbiochem (La Jolla, CA, USA). Radiochemicals
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were purchased from Amersham Corp. (Arlington
Heights, IL, USA).
Cell culture
Normal human keratinocytes (NHK, 2nd–4th pas-
sage) were grown in low calcium containing modi-
fied MCDB 153 medium (KGM, Clonetics, San
Diego, CA, USA, or Medium 154, Cascade Bio-
logics, Portland, OR, USA), as previously de-
scribed (22). At either 20–30% confluence or 100%
confluence, the cells were incubated with or with-
out 3 nM and 3 mM RA for 48 h or with or with-
out 3 mM RA for 4 and 24 h. For inhibitior studies,
confluent cell monolayers were pretreated for 1 h
with either PD153035 (0.2 mM), PD98059 (10 mM)
or SB202190 (3 mM), then treated with or without
3 mM RA for various periods.
Skin biopsies
After obtaining informed consent, split-thickness
skin biopsies (0.2–0.4 mm) were removed from
the buttocks of psoriatic patients or healthy vol-
unteers using a keratome as previously described
(23). All procedures involving human subjects
were approved by the Institutional Review Board
of the University of Michigan. For studies in-
volving in vivo retinoic acid treatment, RA pow-
der was dissolved in 70% ethanol/30% propylene
glycol, applied once to the buttocks, and main-
tained under plastic wrap occlusion, as pre-
viously described (24). Controls were treated with
ethanol/propylene vehicle under identical con-
ditions. After 4 days of treatment, keratome
biopsies were frozen immediately in liquid nitro-
gen prior to RNA extraction.
Organ culture
Keratome strips were cut into 2¿2 cm squares and
frozen either immediately in liquid nitrogen or
transported to the laboratory at room temperature
in low-calcium, serum-free modified MCDB me-
dium without added growth factors (KBM) (Kera-
tinocyte Basal Medium, Clonetics; San Diego, CA,
USA, or Medium 154, Cascade Biologics, Inc.;
Portland, OR, USA) within 15 min. Upon arrival
in the laboratory the tissue was placed, stratum
corneum up, in 35 mm tissue culture dishes and
incubated in KBM at 37æC in a 5% CO2 incubator
in the presence or absence of 3 mM RA, 3 mM tri-
amcinolone acetonide, 0.3 mM TTNPB, 0.3 mM
mc-TTNPB, or 1 mM MC903. After 24 h of in-
cubation, the tissue samples were snap frozen in
liquid nitrogen and processed for RNA isolation
as described later.
HB-EGF gene expression in human keratinocytes and skin
RNA isolation and northern blotting
Total RNA was isolated from cells and human skin
keratome biopsies as previously described (15).
Thirty to forty mg of RNA were separated on 1%
formaldehyde agarose gels, blotted to nylon mem-
branes (Zeta-Probe, Bio-Rad, Richmond, CA,
USA) and hybridized against HB-EGF and 36B4
as previously described (15). Hybridization signals
were visualized by autoradiography and/or quanti-
tated by phosphorimager (Molecular Dynamics,
Inc. Sunnyvale, CA, USA). Quantitated hybridiza-
tion signals were normalized to the control gene
36B4 and expressed as fold change relative to the
values obtained for normal or untreated skin. Stat-
istical analysis of the fold change values was per-
formed using paired or unpaired Student t-tests,
assuming unequal variances and a two-tailed
hypothesis.
Results
Treatment of NHK with 3 mM RA markedly and
significantly increased HB-EGF mRNA express-
ion compared to untreated control cultures at 24
and 48 h, with a clear trend of induction at 4 h as
well (Figs 1A and 1B). High concentrations of RA
(3 mM) inhibited the growth of subconfluent KC
in this system (data not shown). However, the ob-
served results could not be attributed to a reduc-
tion of HB-EGF inducibility in postconfluent KC,
as induction was comparable in confluent and sub-
confluent cells (Fig. 1B). Only very limited and
non-significant induction of HB-EGF was ob-
served in response to 3 nM RA (Fig. 1B), a dose
that induces marked induction of IL-1b mRNA in
keratinocytes (25). Preincubation with 0.2 mM of
the EGFR tyrosine kinase inhibitor PD153035, 10
Figure 1. Retinoic acid increases HB-EGF mRNA expression
in normal human keratinocytes. Total RNA was harvested and
analyzed by quantitative northern blotting as described in Ma-
terial and methods. (A) NHKs were grown in KGM to conflu-
ence and treated with 3 mM RA for 4 and 24 h. Asterisk (*)
denotes significant (P∞0.05) changes relative to untreated con-
trols harvested after the same time intervals. (B) Normal hu-
man keratinocytes were grown to 30% or 100% confluence and
incubated with or without 3 nM or 3 mM RA for 48 h. The
data shown in the bar graph are expressed relative to untreated
controls harvested 48 h after reaching 30% confluence. (C) Con-
fluent normal human keratinocyte cultures were pretreated with
the EGFR tyrosine kinase inhibitor PD153035 (0.2 mM), the
MAP kinase kinase inhibitor PD98059 (10 mM) or the p38
stress-activated protein kinase inhibitor SB202190 (3 mM) for 1
h, then incubated with or without 3 mM RA for 4 h, as indi-
cated above the autoradiograms. Results obtained using kera-
tinocytes from two different subjects are shown. Inhibitor-
treated keratinocytes showed no evidence of cytotoxicity by
phase contrast microscopy (data not shown).
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mM of the MAP kinase kinase inhibitor PD98059
or 3 mM of the p38 stress activated protein kinase
inhibitor SB202190 for 1 h prior to RA treatment
markedly reduced the induction of HB-EGF
mRNA (Fig. 1C). In two experiments, we observed
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Figure 2. Retinoids potentiate HB-EGF gene expression in hu-
man skin organ culture. Keratome biopsy fragments were incu-
bated in the presence or absence of 3 mM RA, 3 mM triamcino-
lone acetonide, 0.3 mM TTNPB or mc-TTNPB, and 1 mM
MC903, as indicated above the autoradiograms. After 24 h,
total RNA was extracted and analyzed by quantitative north-
ern blotting. Quantitative data are shown only for RA. Asterisk
(*) indicates significant (P∞0.05) differences between the re-
sponses obtained in RA-treated vs untreated skin organ cul-
tured for the same length of time.
Figure 3. RA induces HB-EGF mRNA expression in normal
human skin. Normal human skin was treated with 0.025% RA
or vehicle under occlusion. Four days later, total RNA was har-
vested from keratome biopsies and analyzed by quantitative
northern blotting. Results were quantitated as described in Ma-
terials and methods and expressed relative to vehicle treated
skin.
1.1-, 2.2-, and 2.1-fold mean inductions for
PD153035, PD98059 and SB202190 pretreated cul-
tures, respectively, compared to a 4.9-fold increase
in response to RA treatment alone. Consistent
with autocrine activation of keratinocytes via the
EGFR (11), these agents also reduced HB-EGF
mRNA levels in control cells not treated with RA
(Fig. 1C). Results qualitatively similar to those
shown in Figs 1A–C were obtained using the im-
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mortalized human keratinocyte cell line, HaCaT
(data not shown).
The HB-EGF probe consistently hybridized to a
minor, more rapidly migrating band correspond-
ing to a transcript length of approximately 1.5 kb.
A similar band was observed in the original de-
scription of HB-EGF (26), and this ‘‘short form’’
of HB-EGF has recently been cloned and se-
quenced (27). We found no evidence for differen-
tial regulation of the full-length and ‘‘short-form’’
HB-EGF transcripts by RA.
Human skin organ culture provides an attractive
in vitro model for dissecting the early events in
wound healing (15). We have previously shown
that HB-EGF mRNA is rapidly and markedly in-
duced in this system, and that immunoreactive
HB-EGF is formed (15). To evaluate the effects
of RA on HB-EGF expression in this system, we
incubated keratome fragments for 24 h in the pres-
ence of 3 mM RA. As shown in Fig. 2, HB-EGF
was significantly increased over and above the
marked induction previously observed (15) in un-
treated organ cultures. The synthetic retinoid
TTNPB also induced HB-EGF gene expression in
this system, whereas its biologically inactive con-
gener, mc-TTNPB (28), had no effect. Similarly,
induction was not observed upon addition of high
concentrations of the corticosteroid triamcinolone
acetonide (3 mM) or the Vitamin D analogue calci-
potriol (MC903, 1 mM). In fact, at the concen-
tration tested, both agents modestly reduced the
induction of HB-EGF mRNA compared to
DMSO-treated controls (Fig. 2).
Figure 4. HB-EGF is overexpressed in lesional psoriatic skin.
Total RNA was isolated from normal skin of 5 nondiseased
individuals or chronic plaque lesions from 6 different psoriatic
individuals and analyzed by quantitative northern blotting. The
quantitative data are expressed as -fold inductions compared to
normal skin. To accomplish this, the 36B4-normalized HB-
EGF band intensities for each individual were divided by the
mean value obtained for the 5 normal skin controls. The insert
shows autoradiograms of the corresponding northern blot se-
quentially hybridized against HB-EGF and 36B4.
HB-EGF gene expression in human keratinocytes and skin
To determine if retinoids exert similar effects in
vivo, human skin was treated under occlusion with
0.025% RA for 4 days, as previously described
(29). As can be seen in Fig. 3, RA treatment mark-
edly and significantly increased HB-EGF mRNA
levels relative to vehicle controls in skin samples
from 6 different individuals (4.5∫0.8-fold, PΩ
0.006). No differences in HB-EGF expression were
observed in vehicle-treated or occluded control
samples, compared to untreated controls obtained
from the same individuals (data not shown).
To assess the expression of HB-EGF in hyper-
plastic epidermis, we compared its expression in
keratome biopsies of normal and lesional psoriatic
skin. As shown in Fig. 4, HB-EGF transcripts were
markedly induced, relative to the skin of normal
volunteers (12.9∫3.7-fold). There was substantial
patient-to-patient variability in expression of these
transcripts, as previously observed for TGF-a (30).
Nevertheless, the comparison between normal and
lesional skin was statistically significant (PΩ0.024,
by unpaired t-test).
Discussion
Although the hyperproliferative effects of retinoids
on epithelial cells and skin in man and mice are
well described (9, 10, 31, 32), RA-responsive genes
that are directly involved in the regulation of epi-
dermal growth are not yet well characterized. Here
we show that HB-EGF, a heparin-binding member
of the EGF family, is markedly induced in re-
sponse to retinoid treatment in cultured keratino-
cytes, short-term organ cultures, and intact skin
(Figs 1–3). In addition to numerous studies in cul-
tured keratinocytes (reviewed in (11)), recent
studies of transgenic mice overexpressing EGF re-
ceptor ligands as well as EGF receptor knockout
mice strongly support a role for EGF receptor ac-
tivation in keratinocyte hyperplasia in vivo (33–38).
Induction of HB-EGF mRNA was observed not
only in RA-treated skin and organ culture but also
in RA-treated keratinocyte cultures, indicating
that the response is autonomous to the keratino-
cyte and that dermal fibroblasts are not required.
Our results therefore suggest that the effects of RA
on epidermal hyperplasia may be mediated at least
in part by keratinocyte-derived HB-EGF.
We consistently observed a lower molecular
weight form of HB-EGF mRNA, as previously re-
ported (26, 27). The size of this transcript is consist-
ent with that of the recently-reported ‘‘short form’’
of HB-EGF, which has been shown to represent a
probable alternatively-spliced transcript encoding
the first two conserved disulfide loops of the EGF
unit connected to a nine amino acid tail (27). We
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found no evidence for differential regulation of the
long and short forms of HB-EGF by RA.
The marked inhibition of the keratinocyte HB-
EGF mRNA response by inhibitors of EGFR pro-
tein kinase, MAP kinase kinase, and p38 stress-
activated protein kinase was unexpected. However,
RA is known to exert several biological effects that
are difficult to ascribe to nuclear receptor-med-
iated gene transcription (25). In support of this
possibility, note that induction of HB-EGF was
observed only at a pharmacologic (3 mM) concen-
tration of RA, whereas the keratinocyte IL-1b
mRNA responses to RA can be observed at 0.3
nM, a concentration close to the Kd for RA bind-
ing by purified RAR (25). Moreover, analysis of
the published sequence of the HB-EGF promoter
(39) did not reveal the presence of canonical retino-
ic acid response elements (RARE), as previously
identified in the 5ø regulatory elements of other
RA-responsive genes, including CRABP-II (5) and
rat and mouse CRBP (6, 7). We could only identify
one half-site, AGTTCA, 626 bp upstream of the
major transcription start site. We cannot exclude
the possibility that the observed half-site reflects a
novel or variant RARE, or that elements consist-
ing of two half sites may be present in an intron or
upstream of the published HB-EGF DNA se-
quence. Nevertheless, these observations lead us to
question whether the observed effects of RA on
HB-EGF expression can be accounted for by
ligand-dependent transcriptional activation of the
HB-EGF gene. It remains possible that signal
transduction initiated at the cell surface could
merge with nuclear receptor signaling at the level
of receptor phosphorylation (40).
The fact that HB-EGF is markedly overexpress-
ed not only in healing wounds (15), but also in
psoriatic lesions (Fig. 4) forges another link be-
tween psoriatic epidermal hyperplasia and wound
healing (41). Previous studies have shown that ap-
plication of RA before wounding enhanced healing
(42, 43). It is possible that this beneficial effect
could be due to enhanced expression of HB-EGF.
Retinoids are quite effective for acute pustular pso-
riasis, but are less useful as a single agent in
chronic plaque psoriasis because they induce
prominent erythema and sensations of itching or
burning when used at concentrations required to
obtain an antipsoriatic effect (44). We have re-
cently shown that induction of vascular per-
meability factor (VPF) is one of several responses
to EGF receptor activation in organ-cultured skin
(15). It is possible that induction of HB-EGF in
response to pharmacologic concentrations of RA
may induce VPF in chronic plaque lesions, produc-
ing unwanted erythema and irritation even as they
carry out their ‘‘normalizing’’ effects on keratiniz-
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ation and other aspects of keratinocyte differen-
tiation. If confirmed, our findings suggest that ju-
dicious combinations of nuclear-targeted retinoids
and plasma membrane/cytoplasmic-targeted signal
transduction inhibitors could significantly reduce
the side effect of irritation that currently limits the
efficacy of RA in psoriasis and other retinoid-re-
sponsive dermatoses.
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